How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

542 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

441. Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth

; no visceral dissemination (normal liver function tests, normal chest x-ray, etc.); negative CSF PCR result Birth weight at least 800 grams --Prior/Concurrent Therapy-- No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or famciclovir for longer than 120 hours or 5 days; no prior prophylactic acyclovir for risk of herpes simplex virus infection --Patient Characteristics-- Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

2000 Clinical Trials

442. Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System

coagulopathy Birth weight at least 800 grams --Prior/Concurrent Therapy-- No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or famciclovir for longer than 120 hours or 5 days --Patient Characteristics-- Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage Other: No infants known to be born to HIV positive women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2000 Clinical Trials

443. Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

: AST or ALT no greater than 5 times upper limit of normal Renal: Creatinine clearance at least 30 mL/min Other: Not pregnant or nursing; negative pregnancy test; fertile patients must use effective contraception; no history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, or famciclovir Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact

2000 Clinical Trials

444. Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir

) for acute therapy of the current episode of herpes simplex encephalitis (HSE). Patients who are unable to swallow oral medications at the time of study drug randomization (Day 0). Patients who are > 3 days beyond completion of treatment course with intravenous (IV) ACV. Patients who are expected to receive long-term (> 30 days/year) therapy with antiviral medications active against HSV [e.g. ACV, valacyclovir (VACV), famciclovir]. Contacts and Locations Go to Information from the National Library

2002 Clinical Trials

445. Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

of initial presentation with CNS disease. Birth weight greater than or equal to 800 grams. Exclusion Criteria: Infants with either a grade 3 or grade 4 intraventricular hemorrhage (IHV) prior to study enrollment. Breast feeding infants whose mothers are taking acyclovir, valacyclovir, or famciclovir for greater than 120 hours (greater than 5 days). If at any point following enrollment the mother takes these antiviral drugs for greater than 120 hours (greater than 5 days), she will be asked to refrain

2002 Clinical Trials

446. Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth

than or equal to 28 days of age at the time of initial presentation with skin, eyes, and mouth (SEM) disease. Birth weight greater than or equal to equal to 800 grams. Exclusion Criteria: Infants with either grade 3 or grade 4 intraventricular hemorrhage (IVH) prior to study enrollment. Breast feeding infants whose mothers are taking acyclovir, valacyclovir, or famciclovir for >120 hours (>5 days). If at any point following enrollment the mother takes these antiviral drugs for >120 hours (>5 days

2002 Clinical Trials

447. Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

antiviral agent active against herpes simplex virus (e.g., acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, or cidofovir) during and for 28 days after study therapy No concurrent immunosuppressive agents (e.g., cyclosporine) during and for 28 days after study therapy No other concurrent investigational or anti-cancer agents during and for 28 days after study therapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2001 Clinical Trials

448. Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

high-dose acyclovir (more than 800 mg twice daily), valacyclovir (more than 500 mg twice daily), cidofovir (more than 0.5 mg/kg per week), or famciclovir (more than 500 mg/day) except for limited treatment courses at higher doses for varicella-zoster virus infections Concurrent low-dose (≤ 0.5 mg/kg per week) cidofovir allowed for limited treatment courses Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2001 Clinical Trials

449. Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

in greater than physiologic doses) in the 4 weeks prior to baseline. G-CSF and epoietin use are permitted. Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG, clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that ended more than 12 weeks prior to screen. Hepatic mass suggestive of hepatocellular carcinoma Alpha-fetoprotein level greater than or equal to 200ng/mL Evidence of gastrointestinal malabsorption or chronic nausea

2001 Clinical Trials

450. A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

, immunomodulatory or corticosteroid therapy Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection Previous treatment with interferon must have ended at least 6 months prior to screening visit History of ascites, variceal hemorrhage or hepatic encephalopathy Co-infection with HCV or HIV Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein) Contacts and Locations Go to Information from the National Library of Medicine

2002 Clinical Trials

451. Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

to screening Absence of Co-Infection with hepatitis C virus (HCV) or hepatitis D virus (HDV) Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease Less that 1/2 weeks of prior therapy with nucleoside/nucleotide analogue (excluding lamivudine) with activity against HBV (including e.g. famciclovir, tenofovir, ganciclovir, adefovir). No receipt of any of these therapies within 24 weeks prior to randomization into this study. Contacts and Locations Go to Information from

2002 Clinical Trials

452. Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

within 1 month prior to baseline Treatment with immunomodulator drugs (interleukins, corticosteriods for indications other than the treatment of adrenal insufficiency) in the 4 weeks prior to baseline. G-CSF and epoetin use are permitted. Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG, clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that ended more than 12 weeks prior to screen. Hepatic mass suggestive of hepatocellular

2001 Clinical Trials

453. The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children

HSV or VZV, such as acyclovir, famciclovir, ganciclovir, foscarnet, and sorivudine. Probenecid. Aspartamine within 48 hours prior to pharmacokinetic samplings. Patients with the following prior conditions are excluded: Grade 2 creatinine value within the past 30 days. Grade 3 hematologic or hepatic values within the past 30 days. Prior hypersensitivity and/or allergic reaction to acyclovir. Grade 3 or 4 mental status changes within the past 30 days. Prior Medication: Excluded: Acyclovir within 1

1999 Clinical Trials

454. A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed with caution: Acyclovir. Famciclovir. Valaciclovir. Imipenem-cilastatin. Myelosuppressive agents. Patients must have: HIV

1999 Clinical Trials

455. Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS

neoplasia class III (CIN III) on Pap smear (Pap smear required within 6 months of starting study drug). Concurrent Medication: Excluded: Acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, topical trifluride, cidofovir injection or other systemic or topical drugs with anti-herpes activity. Required: >= 10 day course acyclovir at 1-4 gm/day po or 15mg/kg/day IV (not required if there is confirmed in vitro resistance to acyclovir). Contacts and Locations Go to Information from the National

1999 Clinical Trials

456. Economic evaluation of antiviral therapy for the treatment of herpes zoster in immunocompetent adults. (Abstract)

of the cost-effectiveness of the 2 most commonly used oral antiviral treatments that have proven efficacy in patients with shingles: famciclovir and aciclovir (acyclovir). It shows that the clinical advantages of famciclovir over aciclovir are accompanied by potential economic advantages in the form of savings in direct costs to the UK National Health Service of between 2.04 pounds and 16.85 pounds per patient treated. Future economic research to validate the benefits of antiviral treatment should focus

1997 PharmacoEconomics Controlled trial quality: uncertain

457. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Full Text available with Trip Pro

were similar to the effects on viral DNA replication. These data suggest that penciclovir or its oral form, famciclovir, may have clinical utility in the treatment of chronic hepatitis B virus infection.

1994 Antimicrobial Agents and Chemotherapy

458. The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro Full Text available with Trip Pro

, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro. Here we report the functional characterization of a third polymerase mutation (rtV173L) associated with resistance to lamivudine and famciclovir. rtV173L was observed at baseline in 9 to 22% of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV. In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M

2003 Journal of virology

459. Hepatitis B virus infection and liver transplantation. Full Text available with Trip Pro

Hepatitis B virus infection and liver transplantation. 9203930 1997 07 10 2018 11 30 0017-5749 40 5 1997 May Gut Gut Hepatitis B virus infection and liver transplantation. 568-71 Terrault N A NA Veterans Administration Medical Center, San Francisco, CA 94121, USA. Wright T L TL eng Journal Article England Gut 2985108R 0017-5749 0 Antiviral Agents 0 Hepatitis B Vaccines 0 Immunoglobulins 2T8Q726O95 Lamivudine 452-06-2 2-Aminopurine 82115-62-6 Interferon-gamma QIC03ANI02 Famciclovir XII270YC6M (...) hepatitis B hyperimmune globulin AIM IM X 2-Aminopurine administration & dosage analogs & derivatives Antiviral Agents administration & dosage Famciclovir Hepatitis B etiology prevention & control therapy Hepatitis B Vaccines administration & dosage Humans Immunization, Passive Immunoglobulins administration & dosage Immunosuppression Interferon-gamma administration & dosage Lamivudine administration & dosage Liver Transplantation Patient Selection 1997 5 1 1997 5 1 0 1 1997 5 1 0 0 ppublish 9203930

1997 Gut

460. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient Full Text available with Trip Pro

failure, and onset of liver dysfunction was observed when resistant virus was the dominant serum species. In three patients, liver recovery was observed when immunosuppression was stopped and when alternative antivirals were given. Wild type virus appeared to respond to ganciclovir, and to reintroduction of lamivudine. For one patient, introduction of famciclovir was associated with clinical, virological, and histological response.Failure of lamivudine prophylaxis may identify patients at special risk

2000 Gut

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>